Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael Bryan Roe is active.

Publication


Featured researches published by Michael Bryan Roe.


Bioorganic & Medicinal Chemistry Letters | 1999

Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives

Michael Bryan Roe; Adrian John Folkes; Philip Anthony Ashworth; Julie Elizabeth Brumwell; Lal Chima; Sukhjit Hunjan; Ian Andrew Pretswell; Wendy Dangerfield; Hamish Ryder; Peter Charlton

We have synthesised and evaluated a series of anthranilamide based modulators of P-glycoprotein. These studies have identified XR9576(2), a potent inhibitor of P-glycoprotein in vitro and in vivo. The general synthesis and the SAR of these compounds are described.


Bioorganic & Medicinal Chemistry Letters | 2001

Synthesis and in vitro evaluation of a series of diketopiperazine inhibitors of plasminogen activator inhibitor-1.

Adrian Folkes; Michael Bryan Roe; Sukhjit Sohal; Julian Golec; Richard Faint; Teresa Brooks; Peter Charlton

We have synthesized and evaluated a series of diketopiperazine-based inhibitors of PAI-1. These studies resulted in the identification of 34 which inhibited PAI-1 in vitro with an IC(50)=0.2 microM. The synthesis and SAR of these compounds are described.


Journal of Medicinal Chemistry | 2008

New Benzylureas as a Novel Series of Potent, Nonpeptidic Vasopressin V2 Receptor Agonists

Christopher M. Yea; Christine Elizabeth Allan; Doreen Mary Ashworth; James Barnett; Andy J. Baxter; Janice D. Broadbridge; Richard Jeremy Franklin; Sally L. Hampton; Peter Hudson; John Horton; Paul D. Jenkins; Andy M. Penson; Gary Robert William Pitt; Pierre Riviere; Peter A. Robson; David Philip Rooker; Graeme Semple; Andrew Sheppard; Robert Haigh; Michael Bryan Roe

Vasopressin (AVP) is a hormone that stimulates an increase in water permeability through activation of V2 receptors in the kidney. The analogue of AVP, desmopressin, has proven an effective drug for diseases where a reduction of urine output is desired. However, its peptidic nature limits its bioavailability. We report herein the discovery of potent, nonpeptidic, benzylurea derived agonists of the vasopressin V2 receptor. We describe substitutions on the benzyl group to give improvements in potency and subsequent modifications to the urea end group to provide improvements in solubility and increased oral efficacy in a rat model of diuresis. The lead compound 20e (VA106483) is reported for the first time and has been selected for clinical development.


Tetrahedron | 2002

Solid and solution phase syntheses of the 2-cyanopyrrolidide DPP-IV inhibitor NVP-DPP728

Nicolas Willand; Jurgen Joossens; Jean-Claude Gesquière; André Tartar; D.Michael Evans; Michael Bryan Roe

DPP-IV inhibitors have been suggested as potential new treatments for type-II diabetes and 2-cyanopyrrolidides have been reported as potent DPP-IV inhibitors. Alternative synthetic approaches to one such compound, NVP-DPP728, are investigated here. One strategy is based in solution phase and is amenable to scale-up. The other is based on solid phase and is appropriate for the rapid analoging of the structural series.


Bioorganic & Medicinal Chemistry Letters | 2004

Non-peptide oxytocin agonists

Gary Robert William Pitt; Andrzej Roman Batt; Robert Haigh; Andrew Penson; Peter A. Robson; David Philip Rooker; André Tartar; Julie E. Trim; Christopher M. Yea; Michael Bryan Roe


Archive | 1997

Anthranilic acid derivatives as multi drug resistance modulators

Hamish Ryder; Philip Anthony Ashworth; Michael Bryan Roe; Julie Elizabeth Brumwell; Sukhjit Hunjan; Adrian Folkes; Jason Terry Sanderson; Susannah Williams; Levi Michael Maximen


Archive | 2003

Non-peptide gnrh antagonists

Michael Bryan Roe; Andrzej Roman Batt; David Michael Evans; Gary Robert William Pitt; David Philip Rooker


Archive | 2004

Diazacycloalkanes as oxytocin agonists

Peter Hudson; Gary Robert William Pitt; David Philip Rooker; Andrzej Roman Batt; Celine Marguerite Simone Heeney; Michael Bryan Roe


Drugs of The Future | 2006

Nonpeptide oxytocin agonists

Doreen Mary Ashworth; Andrzej Roman Batt; Andrew John Baxter; Pierre Broqua; Robert Haigh; Peter Hudson; Celine Marguerite Simone Heeney; Régent Laporte; Andrew Penson; Gary Robert William Pitt; Peter A. Robson; David Philip Rooker; André Tartar; Chris Yea; Michael Bryan Roe


Archive | 2004

benzamide derivatives as oxytocin agonists and vasopressin antagonists

Peter Hudson; Andrzej Roman Batt; Celine Marguerite Simone Heeney; Andrew John Baxter; Michael Bryan Roe; Peter A. Robson

Collaboration


Dive into the Michael Bryan Roe's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Peter Hudson

Ferring Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robert Haigh

Ferring Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge